Definitive Contract 75F40122C00203

The U.S. Food and Drug Administration (FDA) awarded a $140,460.04 firm fixed-price purchase order contract to Nanoview Biosciences, Inc., a small business concern. The contract is for the provision of the NANOVIEW BIOSCIENCES EXOVIEW R100 system, a specialized imaging equipment used for testing services. This award is a small business set-aside contract and represents the fourth federal contract received by Nanoview Biosciences from the Department of Health and Human Services, including the...

This is a firm fixed-price purchase order contract awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to Precision Nanosystems US Inc., a for-profit small business organization, on August 22, 2022. The contract, valued at $119,600.58, is for the delivery of a NanoAssemblr Ignite bench-top lipid nanoparticle assembler instrument system. The contract has a completion date of October 31, 2023. The contract was set aside for total small business...

The U.S. Food and Drug Administration (FDA) awarded a $3,090,714.59 definitive cost no fee contract to DNA Hive LLC, a small disadvantaged business, to develop a next generation medical countermeasures scientific platform for regulatory evaluation and preparedness under Broad Agency Announcement (BAA) #FY25C3AP3. The contract has an ultimate completion date of September 29, 2028 and was awarded on September 23, 2025. The FDA BAA solicits basic and applied research and development proposals to...

<p>This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA), a civilian agency, to Applied Nanofluorescence, LLC, a small disadvantaged business, for the repair and preventative maintenance (PM) services of a NANOSPECTRALYZER SYSTEM. The contract has a ceiling value of $12,680.04 and an ultimate completion date of July 31, 2023. The contract was set aside for a total small business.</p>

The Food and Drug Administration awarded a $206,125 firm fixed-price purchase order to NanoString Technologies, Inc., a publicly traded provider of advanced genomic analysis platforms and life science tools, for four option years of preventive maintenance services on an nCounter Sprint Profiler Instrument. The contract, which carries a Total Small Business set-aside designation, was awarded on June 21, 2022, with an ultimate completion date of July 31, 2027. The place of performance is...

The Defense Health Agency awarded a $1.3M firm fixed price definitive contract to Tao Treasures, LLC (operating as Nanobiofab) on September 5, 2025, for development of a next-generation rapid infection detection platform leveraging volatile organic compound sensing and artificial intelligence. The contract, designated as a total small business set-aside, supports the creation of an advanced diagnostic system designed to enable precision infection management through non-invasive, real-time...

The Department of Health and Human Services Food and Drug Administration awarded a $22,766 purchase order to Nanostring Technologies, Inc. for the procurement of Nanostring cassettes and reagents. The firm fixed price contract has a period of performance from August 15, 2023 through August 14, 2024 and will be performed in Silver Spring, Maryland. The award is set aside for total small businesses. As the prime contractor, Nanostring will provide its proprietary gene expression analysis...

The U.S. Food and Drug Administration (FDA) awarded a firm-fixed price purchase order contract valued at $327,080 to Molecular Vista, Inc. to procure an atomic force microscope coupled with photothermal infrared imaging capabilities. This acquisition, made under the FDA's Office of Acquisition and Grants Services, responds to a request for quotations seeking a system to physically and chemically characterize nanomaterials in drug products at the nanoscale level. As a total small business...

<p>This is a $149,500.00 Firm Fixed Price contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Nanomedical Diagnostics, Inc., a small business manufacturer, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for the &quot;REAL-TIME ASSESSMENT OF ANTIMICROBIAL CONCENTRATIONS FOR PERSONALIZED TREATMENT OF INFECTIOUS DISEASES.&quot; The contract was awarded on October 24, 2016 with a final completion date of July 23, 2017.</p>

This is a federal contract award from the Defense Threat Reduction Agency (DTRA), a defense agency, to Nanobiosym Inc., a for-profit woman-owned small business. The contract, valued at $2,050,000.00, is for a base period with no set-aside designation. The contract type is a definitive contract with cost-no-fee pricing. The place of performance is East Cambridge, Massachusetts. Nanobiosym Inc. has been awarded federal contracts and grants in the past. Without additional details on the original...